A phase II trial of cisplatin (C), gemcitabine (G) and gefitinib for advanced urothelial tract carcinoma: Results of Cancer and Leukemia Group B (CALGB) 90102 Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Combined Chemotherapy Protocols
  • Carcinoma, Transitional Cell
  • Urologic Neoplasms

abstract

  • The combination of cisplatin, gemcitabine and gefitinib is well tolerated and active in advanced transitional cell carcinoma. The addition of gefitinib does not appear to improve response rate or survival in comparison to historical controls of cisplatin and gemcitabine alone.

publication date

  • June 4, 2009

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC2685451

Digital Object Identifier (DOI)

  • 10.1093/annonc/mdn749

PubMed ID

  • 19168670

Additional Document Info

start page

  • 1074

end page

  • 9

volume

  • 20

number

  • 6